Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023 200 mg), IPTACOPAN clinical trials

A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients

This study is looking into a new medication called LNP023 for a kidney condition called IgA nephropathy. It compares LNP023 with a dummy pill (placebo) to see if it helps reduce protein in the urine and protect kidney function over time.